Marina Gets Institutional Approval to Begin Phase I Study of FAP Drug

"Clinical site approval at MGH marks the last regulatory requirement prior to moving our first drug candidate into human trials," Michael French, president and CEO of Marina, said in a statement.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.